List of pharmaceutical compound number prefixes

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary names may not be warranted, see article on drug nomenclature. Instead, these compounds are usually given a number for internal reference at the company. To distinguish the numbered compounds from different companies (or academic laboratories), each compound number is prefixed with a letter code indicating the company that developed the compound, that claims intellectual property on that compound etc. The letter code is conceived by companies themselves who should be interested in creating a unique code. Three main methods are found for prefixing the numeric identifier – with a space (gap),[1] with nothing (concatenated),[2][3] and with a dash (or hyphen).[4]

For example, ABT-199 is a compound developed at Abbott Laboratories, and this name has been used in early publications of research results. Later the compound was assigned the international nonproprietary name (INN) venetoclax. Similarly, other compounds may be given a USAN or BAN for example. Finally, the compound may be given a trade name for example for marketing purposes.

A long list of code designations with corresponding trade names can be found in Appendix IV of the USP Dictionary, see article on drug nomenclature.

Note that this convention of composing compound identifiers from a company identifier followed by a number is not always followed. For example, the letter code may reflect a therapeutic/disease area or an internal project name. A randomly picked example is SC for spinal cord injury.[5]

A to F[edit]

G to L[edit]

M to S[edit]

T to Z[edit]

References[edit]

  1. ^ a b "ArQule clinical pipeline". Retrieved 2016-09-16.
  2. ^ a b "Regeneron PCSK9 Antibody REGN727". Archived from the original on 2012-04-16. Retrieved 2012-04-17.
  3. ^ a b "Exelixis HSP90 inhibitor XL888". Archived from the original on 2016-09-18. Retrieved 2016-09-16.
  4. ^ a b "AbbVie pipeline, using ABBV- as prefix". Retrieved 2016-09-16.
  5. ^ "SC0806 clinical trial". Retrieved 2018-07-26.
  6. ^ a b "AbbVie spun out of Abbott". Retrieved 2016-09-15.
  7. ^ "ADL5747". Retrieved 2008-03-19.[dead link]
  8. ^ "Adventrx Product List". Archived from the original on 2007-11-16. Retrieved 2007-11-18.
  9. ^ "Amgen goes 6-for-6 in Phase III". Retrieved 2014-11-25.
  10. ^ "ArraY BioPharma – Our Pipeline". Retrieved 2018-12-30.
  11. ^ "Overview of R&D Pipeline" (PDF). Retrieved 2018-12-30.
  12. ^ "Antisense Therapeutics Ltd Home Page". Retrieved 2008-02-20.
  13. ^ a b "Pipeline – AstraZeneca". Retrieved 2018-12-30.
  14. ^ "Edison outlook report on YM Biosciences" (PDF). Retrieved 2016-09-19.
  15. ^ "Eagle Pharmacy – Pharmaceutical Compounding". Retrieved 2016-04-26.
  16. ^ a b "Genentech Pipeline". Retrieved 2016-09-29.
  17. ^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GDC-0152". Journal of Medicinal Chemistry. 59 (23): 10549–10563. doi:10.1021/acs.jmedchem.6b01022. PMID 27682507.
  18. ^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GNE-272". Journal of Medicinal Chemistry. 59 (23): 10549–10563. doi:10.1021/acs.jmedchem.6b01022. PMID 27682507.
  19. ^ "Neurocrine Vmat2 inhibitor NBI-98854". Archived from the original on 2015-01-30. Retrieved 2016-09-13.
  20. ^ "Sunesis BTK inhibitor SNS-062". Retrieved 2016-09-15.
  21. ^ "TH-302 clinical trial". Retrieved 2013-07-23.
  22. ^ "MM&M News". 2008-12-18. Retrieved 2009-02-16.
  23. ^ "TransMolecular Product Pipeline". Archived from the original on 2007-07-29. Retrieved 2007-11-18.
  24. ^ "Taisho Press Release". Retrieved 2008-01-07.
  25. ^ "UCL1684 at pubchem.gov". Retrieved 2018-03-24.
  26. ^ "UCL1684 at tocris.com". Retrieved 2018-03-24.